Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

Sponsor
Seoul National University Hospital
Study ID
NCT02420392
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Dapagliflozin — DRUG
    8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea

Study Details

To investigate the effect of dapagliflozin on the incretin sensitivity of the pancreatic beta cell.

Key Dates

Start date
Feb 28, 2015
Status verified
Apr 2016
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016

Study Design

Enrollment
30 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Dapagliflozin treatment
    Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients
  • No Intervention: Normal glucose tolerance
    Test incretin sensitivity in subjects with normal glucose tolerance

Primary Outcome Measure

Difference of incretin sensitivity of pancreatic beta cell measured by hyperglycemic clamp with GLP-1 and GIP infusion [ Time Frame: From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp ]

Related Studies